Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure Hemopure Advisory Committee For Hemorrhagic Shock Expected By September

This article was originally published in The Pink Sheet Daily

Executive Summary

The FDA committee would likely discuss circumstances under which the agency could lift a clinical hold that has been on the Hemopure trial since the IND was submitted in June 2005.

You may also be interested in...



Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study

Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.

Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study

Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.

FDA’s Emergency Research Regs Will Update “Community Informed Consent”

The agency is open to “possibilities” in terms of revising human subject protections.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel